Use of comparative proteomics to identify potential resistance mechanisms in cancer treatment.
about
Quantitative proteomic and interaction network analysis of cisplatin resistance in HeLa cellsComparative proteomic analysis of paclitaxel sensitive A549 lung adenocarcinoma cell line and its resistant counterpart A549-Taxol.Genomic and oncoproteomic advances in detection and treatment of colorectal cancerIdentification of a new peptide for fibrosarcoma tumor targeting and imaging in vivoProteomic studies coupled with RNAi methodologies can shed further light on the downstream effects of telomerase in glioma.Prediction of individual response to anticancer therapy: historical and future perspectivesDeterminants of 14-3-3σ protein dimerization and function in drug and radiation resistance.Innovations, challenges and future prospects of oncoproteomics.Proteomics of cancer cell lines resistant to microtubule-stabilizing agents.Proteomic methodologies and their application in colorectal cancer research.Current advances in the application of proteomics in apoptosis research.Dissecting cell death with proteomic scalpels.Targeting the MHC Class II antigen presentation pathway in cancer immunotherapy.Nucleophosmin1 associated with drug resistance and recurrence of bladder cancer.Bisphenol, npcRNAs and Utero-Ovarian Feed-Back Control of Breast Cancer Chemosensitivity.Proteomic approach toward determining the molecular background of pazopanib resistance in synovial sarcoma.
P2860
Q28478299-120434E2-51D8-4C50-912A-254EAF4078F6Q30983379-F97AC3CC-8FBA-4344-AEA9-5DAD241FF08AQ33425477-1130A995-309E-4A57-B373-EA21E5E8C861Q33769196-B60EE302-1ACC-4CBE-AD35-C8EF691E7736Q33801496-6DE9B3DB-3135-4750-ABBF-A95C0D97B350Q35024682-A908BDB9-186A-47E4-B8F8-D98BFBC08957Q37272059-D6875D8D-FEF3-413D-99C8-22BD63FF48AEQ37453835-0FB02419-408F-44CB-A4FE-189F94CC6A7EQ37625745-1D96FA3F-F34A-4A41-9001-5BCADFFFC02CQ37643738-A933F248-AB01-4253-B7DF-4BD78FC5D586Q37854521-E278E3C2-6201-4B75-B56C-9E26F1B06752Q37976004-09E3D2E5-E9F7-419A-8A13-B61D9476E435Q38060734-A61EA0AD-DF5B-4351-A604-A537C07B5499Q38985274-DF9E13FD-8DA9-4935-BA20-27937477F12EQ43077439-5983FB4A-F6B5-4B53-8913-1A4362BB0A3CQ50129409-C5B4A10F-9563-4E12-AE5A-5BD2DAD219D2
P2860
Use of comparative proteomics to identify potential resistance mechanisms in cancer treatment.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Use of comparative proteomics ...... echanisms in cancer treatment.
@ast
Use of comparative proteomics ...... echanisms in cancer treatment.
@en
type
label
Use of comparative proteomics ...... echanisms in cancer treatment.
@ast
Use of comparative proteomics ...... echanisms in cancer treatment.
@en
prefLabel
Use of comparative proteomics ...... echanisms in cancer treatment.
@ast
Use of comparative proteomics ...... echanisms in cancer treatment.
@en
P2860
P1476
Use of comparative proteomics ...... echanisms in cancer treatment.
@en
P2093
Jian-Ting Zhang
P2860
P304
P356
10.1016/J.CTRV.2007.07.018
P577
2007-09-12T00:00:00Z